incub8coalition Profile Banner
INCUBATE Profile
INCUBATE

@incub8coalition

Followers
259
Following
177
Media
238
Statuses
1K

We foster innovation, safeguard advancements, and amplify the results of life sciences investment.

Joined February 2019
Don't wanna be here? Send us removal request.
@incub8coalition
INCUBATE
22 days
@johnbstanford joined a breakout session at @BIOConvention on how to align policies impacting drug development with unmet patient need, where he discussed how policy can support innovation in areas like cancer and rare diseases.
Tweet media one
0
0
0
@incub8coalition
INCUBATE
19 hours
Nearly 5 million people die annually due to antibiotic resistance. Small molecule antibiotics are essential in the fight against this global health crisis. Read more in Incubate's white paper:
Tweet media one
0
0
0
@incub8coalition
INCUBATE
1 day
Small molecule companies are "not the cool kid in the class anymore," @johnbstanford told @PharmaVoice. He outlines Incubate's survey findings on how the IRA, tariffs, and NIH cuts are shaking biotech CEOs confidence -- and what that means for Washington.
Tweet media one
0
1
1
@incub8coalition
INCUBATE
3 days
Incubate submitted a comment to @USTradeRep opposing proposed MFN drug pricing policy that could reduce U.S. biotech investment, delay access to new treatments, and weaken U.S. leadership in the sector.
Tweet media one
0
0
0
@incub8coalition
INCUBATE
6 days
"We want foreign investors coming to U.S.-based companies to develop drugs for the world." @johnbstanford spoke with @FierceBiotech at this year's @BIOConvention about supporting a robust U.S. life sciences sector.
0
1
1
@incub8coalition
INCUBATE
7 days
Last week, @johnbstanford joined @PunchbowlNews for a fireside chat on the future of medicine, stressing the need to sustain U.S. leadership in life sciences and boost investment in small biotechs developing lifesaving treatments.
Tweet media one
0
1
2
@incub8coalition
INCUBATE
8 days
At this year's @BIOConvention, Incubate placed an ad in the @BostonGlobe urging Congress to end the pill penalty and pass the EPIC Act. We're proud to stand with investors calling for policies that protect progress in medicine.
Tweet media one
0
0
1
@incub8coalition
INCUBATE
9 days
"Startups are being forced to make hard choices: shelve promising programs, pull back on trials or pivot away from entire classes of cutting-edge and potentially life-saving drugs." @johnbstanford in @BioSpace on why Congress must pass the EPIC Act.
0
1
0
@incub8coalition
INCUBATE
9 days
"What are we going to do from a national security perspective when China has the cure for diabetes?" @johnbstanford at last week's @PunchbowlNews fireside chat, stressing that when the U.S. falls behind in biotech, it poses a risk to our medical supply chains.
0
1
2
@incub8coalition
INCUBATE
10 days
The seventh edition of Incubate Shorts is here! Incubate's policy director John Guy speaks with Victoria Ford, CEO of @txhbi, about why passing the EPIC Act and opposing MFN drug pricing is critical to supporting 9200 biotech and life science companies across Texas. Watch here:
0
0
0
@incub8coalition
INCUBATE
13 days
Ahead of the DOJ & FTC listening session on barriers to generic and biosimilar competition, remember that patent protections are what enable the high-risk investments necessary to discover breakthrough therapies and improve upon existing treatments.
0
1
0
@incub8coalition
INCUBATE
14 days
In an op-ed for @BioSpace, Incubate's executive director @johnbstanford highlights how recent policy changes are driving investors away from biotech. He calls on Congress to pass the EPIC Act to support new treatments and restore confidence in the sector.
0
0
1
@incub8coalition
INCUBATE
15 days
The sixth edition of Incubate Shorts spotlights Patrick Jordan, Managing Partner of NovaQuest Capital Management and Chairman of @MycoviaPharma, who highlights the need to foster therapeutic innovation by ending the pill penalty and strengthening IP protections. Watch here:
1
0
0
@incub8coalition
INCUBATE
15 days
HHS Secretary RFK Jr. announced his support this week for fixing the pill penalty, noting it has dampened small molecule innovation. Addressing it is key to maintaining U.S. biotech leadership, investment, and research.
0
0
0
@incub8coalition
INCUBATE
15 days
This morning, @johnbstanford joined @PunchbowlNews for a fireside chat on the future of medicine. He emphasized that "science is no longer the barrier" to medical progress, but that we need the political will to sustain U.S. dominance in biotech.
Tweet media one
0
0
0
@incub8coalition
INCUBATE
16 days
RT @PunchbowlNews: Now, John Stanford, Incubate’s founder and executive director, and Janis Naeve, venture partner at Cota Capital, join An….
0
2
0
@incub8coalition
INCUBATE
16 days
RT @PunchbowlNews: Happening Now – The Future of Medicine: A Conversation with Rep. Greg Murphy @repgregmurphy
0
5
0
@incub8coalition
INCUBATE
16 days
In the fifth edition of Incubate Shorts, @AURP Chief Strategy Officer Brian Darmody joins Incubate’s Policy Director John Guy to discuss how MFN drug pricing and indirect cost cuts could affect biotech research grants for universities. Watch their interview:
1
1
0
@incub8coalition
INCUBATE
16 days
The fourth edition of Incubate Shorts is here! @johnbstanford speaks with Tim Scott, CEO of @BiocomCA, about California's thriving life sciences industry, including the need to protect the state from MFN drug pricing and the vital role of strong patient protections. See more:
1
0
0
@incub8coalition
INCUBATE
16 days
Tune in tomorrow at 9 am ET for a fireside chat with @johnbstanford and @PunchbowlNews on the future of medicine and innovation. The event opens with remarks from @RepGregMurphy. Register here:
0
0
0
@incub8coalition
INCUBATE
22 days
The third edition of Incubate Shorts spotlights Maria Thacker Goethe, CEO of @Georgia_BIO. In a conversation with Incubate's Policy Director, John Guy, Maria warns that adopting Most Favored Nation drug pricing could jeopardize U.S. global competitiveness. Watch the interview:
1
0
0